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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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Etiology and epidemiology 
Echinococcosis, also called hydatidosis or hydatid disease, is a zoonotic disease caused by various species of 
cestode parasites of the genus Echinococcus. It is recognised by the World Health Organization (WHO) as one of 
16 diseases or disease groups considered to be “Neglected Tropical Diseases”. 
While there are several pathogenic species of Echinococcus, with four species considered to infect humans, most 
of the global concern caused by echinococcosis is due to infection with E. granulosus, and its ability to generate 
hydatid cysts in humans. E. granulosus causes what is known as cystic echinococcosis (CE).  This report focuses 
on echinococcosis caused by E. granulosus. Hydatid disease occurs in Africa, Europe, Asia, the Middle East, 
Central and South America. E. granulosus is transmitted between the definitive hosts which are the canids, dogs 
mainly, and herbivorous intermediate hosts, in most cases sheep and goats. The parasite is transmitted to dogs 
when they ingest the organs of other animals that contain hydatid cysts. The cysts develop into adult tapeworms 
in the dog. Infected dogs shed tapeworm eggs in their feces which contaminate the ground. Sheep, cattle, goats, 
and pigs ingest tapeworm eggs in the contaminated ground; once ingested, the eggs hatch and develop into 
cysts in the internal organs. The most common mode of transmission to humans is by the accidental 
consumption of soil, water, or food that has been contaminated by the fecal matter of an infected 
dog. Echinococcus eggs that have been deposited in soil can stay viable for up to a year. 
With the advent of DNA technology, genotypes have been defined. Of these, it has been determined that the 
G1-3 genotype(s) are responsible for up to 88% of all human cases of hydatid disease worldwide, followed by a 
camel and goat transmitted genotype, G6, causing 7% of human infections and a pig transmitted genotype, G7, 
causing 3% human infections.CE in humans is a chronic disease. Humans with CE often remain asymptomatic 
until hydatid cysts containing the larval parasites grow large enough to cause discomfort, pain, nausea, and 
vomiting. The cysts grow over the course of several years before reaching maturity and the rate at which 
symptoms appear typically depends on the location of the cyst; sudden death may occur. In livestock symptoms 
are likely to be the same as in human, while in dogs there are no clinical signs. 
 
Diagnostics 
A wide range of diagnostic tools exists for human. For livestock, most of the diagnostic tests described in the 
abundant literature on the subject are not reliable, mainly due to a weak or no specific antibody response to the 
disease in many infected animals and because of the almost ubiquitous infection of livestock species with closely 
related, and antigenically cross-reacting, taeniid cestode species. Post mortem examination of liver and lung 
tissues remains the only reliable method for diagnosis of infection in livestock animals. Similarly in dogs, because 
of the fact that eggs of all taeniid cestode species are morphologically indistinguishable and wherever E. 
granulosus is transmitted, so are a number of other species of taeniid cestode; traditional egg examination of 
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faeces is not reliable. Definitive diagnosis in dogs can only be made by examination of the small intestine at 
necropsy, or examination of worms voided in an intestinal purge induced after administration of appropriate 
drugs. PCR-based methods are also valuable, and specific, although they lack sensitivity in the case of low worm 
burdens. The progress made to date in the development of more reliable diagnostic tools requires further work, 
aspects of which are discussed in the present monograph.  
 
Incidence / Prevalence and Impact 
Under-reporting is a major problem for CE globally: this is clearly visible in the data from the OIE and the AU-
IBAR. In many countries where there are no reports on animal cases, such as in South Africa, there are human 
cases reported.  It is presumed that livestock reports are based on slaughter findings, but this is not certain as no 
details on the information are available. In most cases conclusions are drawn from human cases even though 
there, also no reliable data are available. The worldwide incidence of CE is estimated to amount to 100,000-
300,000 cases annually, with the disease known to occur in all continents and in at least 100 countries. 
According to a 2015 WHO report on neglected tropical diseases, in regions where cystic echinococcosis is 
endemic the incidence in humans can exceed 30/100 000 person-years; prevalence as high as 5–10% may occur 
in parts of South America, Central Asia, China and Africa. The postoperative death rate for surgical patients is 
2.2%; 6.5% of cases relapse after intervention and require prolonged recovery time. Human echinococcosis can 
be life-threatening if undiagnosed and untreated. Treatment often includes costly surgery. Taking into 
consideration the public health impact, condemnation at slaughter, production losses and other economic 
burden in developing countries, other studies estimate the annual global economic losses due to CE in livestock 
to be over US$2Billion. 
 
Control 
Because humans infected with CE pose no risk to other humans, all efforts to control transmission of the disease 
must be implemented either towards reducing the exposure of humans to the parasite (sanitation, exposure to 
infected dogs) or intervention measures directed towards the animal hosts. From experiences gained in some 
countries that had implemented control programs, a combination of approaches is required, taking into 
consideration local circumstances, socio-political and other realities and constrains. Situations such as the 
presence of stray dogs in certain countries would add to the difficulties in prescribing universal approaches. 
Treatment: In humans, treatment with essentially Albendazole forms an important aspect of disease 
management.  However, to be effective the drugs are required to be given in large amounts over long periods of 
time. No practical treatment has been developed for livestock animals.  Infected dogs can be treated and 100% 
cured with a single dose of Praziquantel. However, there is no effective immunity in dogs, thus exposing them to 
re-infection with Echinococcus, in the absence of an effective control program.  
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Prophylaxis: A sheep vaccine has been developed and evaluated in several situations, showing that it can greatly 
reduce transmission of E. granulosus by livestock animals (including goats and cattle challenges with the G1-3 
genotype(s)). 
A number of options and strategies for control programs at national, sub-national or regional level can be 
considered. These would include elements of  
• Control of non-owned dogs 
• Prevention of dogs gaining access to infected offal 
• Treatment of dogs 
• Quarantine of infected livestock 
• Vaccination 
Mathematical modelling of the transmission parameters for CE using various CE control options including the 
EG95 vaccine, showed that the use of vaccination together with relatively infrequent treatment of dogs, 
provided the optimal level of control with a relatively minimal cost. Although wildlife is known to contribute to 
some degree to CE transmission in many parts of the world, wildlife transmission is not considered to be a major 
source of human infection in highly endemic regions of the world. CE control measures are more appropriately 
directed towards domestic transmission of the disease rather than sylvatic transmission. 
 
Current Vaccines 
There is no existing vaccine to prevent or reduce Echinococcus infection in dogs. There is little evidence to 
support the existence of protective immune responses against infection with Echinococcus or other taeniid 
cestode species in their definitive host and it appears that the prospect for development of a vaccine against the 
adult parasite, which resides in the intestinal lumen, is poor. A livestock vaccine based on a recombinant antigen 
from the oncosphere life-cycle stage of the parasite, known as EG95, has been developed by the University of 
Melbourne and successfully evaluated in independent experimental trials undertaken in sheep in Australia, New 
Zealand, Argentina, Chile, Iran, China and Romania, and also in goats and cattle. The vaccine has demonstrated a 
reliable, high level (>90%) protection against a challenge infection with E. granulosus. The EG95 vaccine is 
produced by local manufacturers in Argentina and China. However, neither company appear to be GMP 
compliant, and GCP data on these vaccines (that have been formulated different from the original) are not 
available.  Field data is also very limited. There is no to date a human vaccine, although the immunological 
characteristics of E. granulosus infection in humans would suggest that the EG95 vaccine would likely be 
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The future of cystic Echinococcosis vaccines and vaccination 
Data generated to date, point towards the need for combination vaccines, produced under GMP, and evaluated 
in a natural transmission environment. A clear opportunity exists for the development of combination vaccines 
incorporating EG95 into existing clostridial vaccines commonly used in young livestock that are at risk of 
echinococcosis. Such combinations provide a potential solution to the lack of economic incentive perceived by 
livestock owners to prevent echinococcosis in their animals.There is a need for field validation of the 
effectiveness of livestock vaccination with the EG95 vaccine in order to formulate new guidelines for control of 
the disease. There is a need to evaluate whether the current EG95 vaccine is effective against other genotypes, 
as to broaden its scope.  
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Echinococcosis refers to a group of diseases caused by various species of cestode parasites of the genus 
Echinococcus.  Alternative nomenclatures for these diseases include hydatids and hydatid disease.  The name 
echinococcosis was adopted after an expert committee established by the World Association for the 
Advancement of Veterinary Parasitology published a Standardized Nomenclature of Animal Parasitic Diseases [1].  
The committee’s recommendations have not been accepted universally and the term hydatid disease remains in 
use, as well as echinococcosis.  Echinococcosis in humans is a zoonotic disease. It is formally recognised by the 
World Health Organization (WHO) as one of 16 diseases or disease groups considered to be Neglected Tropical 
Diseases and the WHO is actively promoting the development and implementation of strategies to decrease the 
incidence of echinococcosis [2].  The WHO and other agencies have issued joint, comprehensive, official 
Guidelines for Surveillance, Prevention and Control of Echinococcosis/Hydatidosis [3], however they are in dire 
need of review and updating.  It is likely the WHO would welcome and value assistance in updating these 
guidelines (M. Lightowlers, personal communication).  
 
Etiology and Epidemiology 
 
Several species of Echinococcus cause hydatid disease.  Taxonomy within the genus Echinococcus is complex and 
evolving.  Over much of the preceding century, four species were considered to infect humans: Echinococcus 
granulosus, Echinococcus multilocularis, Echinococcus vogeli and Echinococcus oligarthrus.  The latter two 
species are restricted to Central and South America and are relatively rare.  E. multilocularis causes alveolar 
echinococcosis (AE), a highly dangerous, metastasising form of disease. It is restricted to the northern 
hemisphere and, while it is endemic in many central and northern European countries, as well as central Asia 
and North America, other than in some relatively restricted parts of China and Tibet, its prevalence in humans is 
in the order of 0.1 per 100,000 population. More recently a new species similar to E. multilocularis has been 
identified from the Qinghai-Tibet plateau in China, Echinococcus shiquicus [4].  E. granulosus causes what is 
referred to as cystic echinococcosis (CE). 
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Most of the global concern caused by echinococcosis is due to infection with E. granulosus, and due to it causing 
hydatid cysts in humans.  
Livestock play a critical role in transmission of E. granulosus that leads to human disease, and echinococcosis in 
humans is a substantial burden on poor rural pastoral communities.  E. granulosus is transmitted between canid 
definitive hosts and numerous species of mainly herbivorous hosts that act as intermediate hosts.  Worldwide, 
sheep and goats play the most dominant role in transmission of E. granulosus.  Dogs harbour a small tapeworm 
in the small intestine. Mature, infective eggs are released with the faeces of an infected dog.  Following 
ingestion of the egg by a suitable species of intermediate host, the parasite within the egg, known as an 
oncosphere, is released, becomes active, penetrates the gut and enters the blood stream. The oncosphere exits 
the circulation within the tissues and establishes a cystic metacestode stage which matures slowly, only 
becoming fertile and able to achieve transmission after a developmental period lasting more than a year.  The 
liver and lungs are the most common sites in which the cysts (hydatid cysts) develop, although cysts may occur 
in any body organ.  Ingestion of mature, infective cyst contents by a dog leads to the development of the 
tapeworm stage, completing the life cycle. The common use of shepherd dogs perpetuates transmission of E. 
granulosus such that the disease is endemic throughout the world where pastoral activities predominate. 
E. granulosus has long been known to be a pleomorphic species, with what has been described as ‘strains’ that 
differed in host preference and other attributes.  Following the advent of DNA-based taxonomic tools, a variety 
of genotypes have been defined, several of which are believed to warrant elevation to species status [5].  Many 
of these genetic variants rarely or never cause human disease [6].   One genotype is responsible for almost all 
human cases of hydatid disease: the G1-3 genotype(s), which causes 88% of infections worldwide.  A camel and 
goat transmitted genotype, G6, causes 7% of human infections and a pig transmitted genotype, G7, causes 3% 
human infections that have been genotyped up until 2014 [6].  The G6 and G7 genotypes are closely related and 
the species name Echinococcus canadensis has been suggested for these genotypes.  The G1-3 genotype(s) is 
referred to as Echinococcus granulosus sensu stricto or E. granulosus s. s. Hereinafter, the terms echinococcosis 
and CE will refer to infections with E. granulosus s. s. unless otherwise indicated. 
Transmission of E. granulosus s. s. occurs between dogs and livestock animals in a prey-predator cycle (Figure 1).  
Transmission does not occur between dogs, nor between infected livestock animals or between humans.  
Accidental ingestion of parasite eggs from the faeces of an infected dog transmit the disease to both livestock 
and humans. Transmission to dogs occurs through them ingesting hydatid cyst material in the viscera (typically) 
of infected livestock.  Deliberate feeding of farm dogs with unsightly offal containing hydatid cysts has been a 
major cause of CE transmission leading eventually to human disease. Scavenging of animal carcases by farm 
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Figure 1: Life cycle of E. granulosus (Source CDC: http://www.cdc.gov/parasites/ echinococcosis/biology.html  
 
E. granulosus eggs are considered to be highly susceptible to desiccation and heat as are the eggs of other 
species of taeniid cestode.  Little direct information is available about the survival of E. granulosus eggs per se.  
At least some eggs of the related species Taenia hydatigena are known to survive on pasture for at least 12 
months in the relatively favourable conditions pertaining in New Zealand [7]. A single publication [8] suggests a 
more substantial ability of E. granulosus to persist in the environment, however those findings are at odds with 
substantial evidence to the contrary and the matter remains to be resolved by further study.  
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Relevance to vaccine protection: An effective vaccine has been developed which can prevent or reduce E. 
granulosus s.s. infection in sheep and other livestock species [9]. The vaccine, based on a recombinant antigen 
known as EG95 (developed from a G1-3 genotype), has been highly effective in experimental vaccine trials 
carried out in sheep in several countries. The mRNA encoding the EG95 homologue has been cloned and 
sequenced from E. canadensis (G6 and G7) and found to be different both in amino acid sequence and 
antigenicity [10].  It is yet to be determined whether the EG95 vaccine is capable of protecting animals against a 
heterologous infection with E. canadensis, or whether the homologue from E. canadensis would be effective as 




In most species of animal, and in humans, CE cysts grow slowly; macropod marsupials appear to be an exception 
[11].  Hence, CE is a chronic condition. Symptoms in humans vary greatly depending on the location, size and 
number of cysts.  Upper abdominal pain is a common initial symptom of liver infections.  Sudden death may 
occur due to anaphylactic-like reactions following accidental rupture of a hydatid cyst.  Patients may asphyxiate 
following the rupture of a lung cyst.  Infected livestock are likely to suffer similar clinical symptoms to those seen 
in humans, however differential diagnosis of a case of sudden death in a sheep or goat is rarely investigated.  




The OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals includes a chapter on Echinococcosis 
/Hydatidosis [12], however it needs to be updated. A comprehensive review on the topic of diagnosis has been 
published recently [13]. 
• Human: Excellent serological tests are widely available for diagnosis of human CE.  These are 
supplemented by the use of imaging techniques and parasitological examination of samples removed 
during surgical procedures. 
• Livestock:  Despite many publications claiming the contrary, there are no reliable serological methods 
for diagnosis of hydatid infection in animals (M. Lightowlers, personal communication).  The failure of 
serological diagnosis in animals arises due to two issues: a weak or non-existent specific antibody 
response to the disease in many infected animals [14][15] and because of the almost ubiquitous infection 
of livestock species with closely related, and antigenically cross-reacting, taeniid cestode species. A 
number of publications have described the use of ultrasonography for diagnosis of ovine echinococcosis, 
however the practical value of such an approach is unclear and ultrasonography does not permit reliable 
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detection of pulmonary echinococcosis. The only reliable method for diagnosis of infection in livestock 
animals is through post mortem examination of liver and lung tissues.  
• Dogs: The eggs of all taeniid cestode species are morphologically indistinguishable and wherever E. 
granulosus is transmitted, so are a number of other species of taeniid cestode, notably T. hydatigena 
which has a very similar lifecycle.  For this reason, traditional parasitological examination of faeces for 
the presence of eggs is unable to be used to specifically diagnose the presence of E. granulosus.  
Definitive diagnosis is made by examination of the small intestine at necropsy [13], or examination of 
worms voided in an intestinal purge induced by the drug arecoline hydrobromide.  Following the 
discovery that dogs produce specific antibodies against infection with taeniid cestode parasites, 
including E. granulosus [16][17], serology was used in several epidemiological studies, however the 
methods used all relied on the application of inappropriate control samples [18] such that the validity of 
serological for diagnosis of infections in naturally infected dogs remains unclear.  More recently, 
coproantigen (coproAg) detection methods and PCR analysis of faecal samples (coproPCR) have been 
developed which are more practical and provide good diagnostic sensitivity and specificity [13]. 
CoproAg tests are usually genus-specific for Echinococcus spp., although depending on the endemic region and 
study aims, coproAg tests have been developed and validated to test for infection with E. multilocularis in foxes 
and dogs or primarily for E. granulosus. For canine echinococcosis due to E. granulosus most authors report 
reasonable sensitivity (78–100%) and good genus specificity from 85% to greater than 95%, as well as a degree 
of pre-patent detection. Where cross-reactions occur these generally appear to be caused by infection with T. 
hydatigena, the most common taeniid of dogs, and attempts to improve specificity by using monoclonal 
antibodies in coproAg tests have not been able to eliminate this problem. CoproAg sensitivity broadly correlates 
with worm burden of E. granulosus, however some low intensity infections (worm burdens <50–100) may give 
false negatives in coproAg tests [13]. The commercial availability of coproAg tests has been problematic, with two 
kits discontinued in Europe (Chekit Bommeli, Switzerland; Genzyme VirotechGmbH, Germany). Currently 
commercial tests appear restricted to three coproAg kits for canine echinococcosis produced in China (i.e. 
Shenzhen Combined Biotech Co., Ltd.; Zuhai Special Economic Zone Haitai Biological Pharmaceuticals Co., Ltd.; 
Xinjiang Tiankang Animal Husbandry Biotech Co., Ltd.). These three China-based kits were recently assessed, 
against a parasitologically defined panel of dog faecal samples by the Institute of Parasitic Disease Prevention 
and Control, Sichuan CDC (also in China) and found to be of variable sensitivity and specificity, with the best kit 
providing a reported 60% sensitivity and 93% specificity [19].  There is a shortage of properly validated control 
samples from animals with parasitologically proven levels of infection and tests are commonly established in-
house by researchers and laboratories associated with CE control activities however.  Hence, the in-house tests 
rely on the published specificity/sensitivity results of other workers and hence are not adequately validated. 
 
The advantage of coproPCR methods is their ability to differentiate E. granulosus infections specifically. Some of 
the published methods have also been able to differentiate infections with the different genotypes of E. 
granulosus.  Due to the expense involved in using PCR as a diagnostic tool and the large numbers of samples that 
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are required to be processed as part of a disease control program, the currently recommended methods are to 
screen canine faeces by coproAg testing and to confirm samples that test positive by coproPCR [13]. 
Main needs for diagnostics: 
a) A coproAg test that is specific for E. granulosus.  
b) A coproPCR test that is amenable to be undertaken by non-specialists which matches the sensitivity 




As indicated above, the global importance of echinococcosis is due, virtually entirely, to the impact of the 
disease on the human population. While the WHO clearly recognises CE as a global health concern and a burden 
on many poor pastoral communities, there is a deficiency in data available about the actual disease burden.  The 
reasons for this situation are numerous, but major contributors are under-diagnosis, misdiagnosis and the 
chronic nature of the disease in most patients.  Accounting for under-reporting, Budke et al. [20] estimate the 
annual global burden of CE to be >1M DALYs and >US$7.6B per year.  
As already mentioned, the genotype cluster comprising genotypes G1, G2 and G3 is responsible for the great 
majority of human infections (88% worldwide) and the principal intermediate host is sheep.  The closely related 
genotypes G6 and G7 cause a significant number of human infections (11% worldwide).  The G6 strain is known 
from Africa and Asia, where it is transmitted mainly by camels and in some instances, goats.    
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The worldwide incidence of cystic echinococcosis is estimated to amount to 100,000 to 300,000 cases annually 
[21] and is known to occur in all continents and in at least 100 countries. Increased prevalence of the parasite are 
found in parts of Europe, around Mediterranean region (variable between 1 and 8 per 100,000), the Russian 
Federation, China, Africa (prevalence >3%), Australia, and South America (9.2 per 100,000 population). In East 
Africa, Kazakhstan, Kyrgyzstan, Northwest-China, and Tibet, it has been observed that the rural populations are 
particularly at risk. Iceland and Greenland are free of echinococcosis, while only sporadic cases in domestic 
animals have been documented in New Zealand, Tasmania, southern Cyprus, Pacific region, and Caribbean [22].   
The lack of data on echinococcosis arises from the absence of systematic programmes to generate these data, 
which remain fragmented. As a result, the global distribution of cystic echinococcosis has changed little since 
2010. See Figure 2.  
It is important to note, that human publications are mainly related to unusual cysts locations, or surgeries, and 




Echinococcosis is a disease that produces almost no clinical signs in livestock; therefore reports to the OIE or AU-
IBAR are very limited.  It is presumed reports are based in slaughter findings, but it is not certain as no details on 
the information are available. 
Due to the nature of the disease, it would be more appropriate to evaluate the prevalence/incidence of human 
cases; however, there is no reliable data either.   
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Figure 2: Distribution of Echinococcus granulosus and cystic echinococcosis worldwide, 2012. 
Source: Third WHO report on neglected tropical diseases. Investing to overcome the global impact of 
neglected tropical diseases, 2015 
 
There are two main sources, OIE and AU-IBAR (which includes only Africa), but data are not always similar.   
 
1- Source: OIE.   
Data of outbreaks reported to the World Animal Health Organization (OIE) are shown in Tables 1 and 2.  Data 
are not always reliable, as many countries doesn’t seem to report, or to be reporting consistently over time.   
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
 
Similar information but presented in a different manner can be seen in Annex 1.   
Number of cases reported to the OIE by disease and by country: 
     -   No information,      +   Present but quantitative data not known,   ?  Disease suspected 
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Table 1: ASIA – Echinococcosis/hydatidosis outbreaks (2005-2013) and Infection with Echinococcus 
granulosus (2014) notified to OIE from the Asian countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - + + + + + + + + - 
India - - - - - - - - - - - 
Indonesia 0 0 - 0 - - - - - - - 
Myanmar 0 1 - - 2 8 2 3 3 1 - 
Nepal 0 0 0 0 0 48 + 0 0 + + 




Table 2: AFRICA – Echinococcosis/hydatidosis outbreaks (2005-2013) and Infection with Echinococcus 
granulosus (2014) notified to OIE from the African countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso - - - - - - - - - - - 
Ethiopia +? +? +? +? +? +? +? +? 0 0 - 
Ivory Coast 0 0 0 ? 0 0 0 0 0 - - 
Kenya ? ? ? ? ? ? ? ? ? 0 - 
Madagascar 0 0 0 0 0 0 0 0 0 0 - 
Malawi ? ? ? ? ? ? ? ? ? - - 
Mali 0 0 - - +? - - - - 0 - 
Mozambique + >1 >1 2 4 2 0 0 + - - 
Rwanda - - - 0 - - - - - - - 
Senegal - - - - - - - -- - - - 
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South Africa 0 0 0 0 +? +? +? 0 0 0 - 
Tanzania + + + - +? +? +? +? +? - - 
Uganda - + +? +? +? +? +? +? +? - - 




The OIE, also includes zoonoses data. The number of human cases and deaths are reported by the countries. 
Data from the countries of interest can be seen in Table 3 below.  It is interesting to note that some countries 
haven’t confirmed animal cases (Vietnam, Ethiopia, Kenya, Madagascar, Malawi and South Africa), however they 
have reported human cases.  That only confirms a big level of underreporting.  
http://www.oie.int/wahis_2/public/wahid.php/Countryinformation/Zoonoses  
 
Table 3: Human cases and deaths due to Echinococcosis/hydatidosis 
 
 
C: Cases,  D: Deaths 
 





Nepal C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Vietnam C: +, D: +
Burkina Faso
Ethiopia C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Ivory Coast
Kenya C: 5, D: 0 C: +, D: + C: 3, D: 0 C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Madagascar C: +, D: + C: +, D: + C: +, D: +
Malawi C: +, D: +
Mali
Mozambique C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Rwanda
Senegal
South Africa C: +, D: + C: +, D: + C: +, D: + C: 440 C: +, D: + C: +, D: + C: +, D: +
Tanzania C: +, D: +
Uganda
Zambia
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2- Source: AU-IBAR. 
Number of outbreaks per year as reported to AU-IBAR and published in the Pan African Animal Resources Year 
Book. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=)  
Table 4 shows the number of Echinococcosis/hydatid outbreaks reported to AU-IBAR.  The information is the 
total reported, and there is no breakdown per country.  
 
Table 4: Number of Echinococcosis/hydatid outbreaks per year as reported to AU-IBAR and published in the 
Pan African Animal Resources Year Book.   
 
 2009 2010 2011 2012 2013 2014 
# Countries affected  3 4 4 2 3 
# Outbreaks 85 27 47 141 128 90 
# Cases 2,809 497 2,443 2,365 876 488 
# Deaths 209 122 161 428 0 2,786 




Prevalence data by country 
• Sources: PubMed, and internet engine searches (English and French when applicable).   
• Conference abstracts: 
a. The XXVI World Congress on Echinococcosis, 2015, Bucharest, Romania 
b. XXV World Congress on Echinococcosis, 2013, Sudan. 
c. XXIV World Congress of Hydatidology, 2011, Urumqi, China. 
• Efforts have been made to include the year of the study, and not the year of the publication. If they are 
known to be different, the year of publication is included in the reference.  
• Note that not all papers have been read in full. In many cases, only the abstracts have been read. Critical 
evaluation of the papers for inclusion has not been conducted 
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• Animals:     
Year Area Species of animal No. samples tested % positive Reference 
2012 Chittagong Cattle and buffaloes 











Dinajpur Slaughtered cattle  25.67 Basak et al, 
2011 
2008  Cattle, buffaloes, 
Goats and sheep 
Cattle: 1460 
Buffaloes: 620 








Kabir et al, 
2010 
2007 Barisal Buffaloes 80 2.5 Ahmedullah, 
2007 
2003 Cox’s Bazar Sheep, buffaloes, 
Cattle and goats 
 Sheep: 52.11, Buffaloes: 
36.11, Cattle: 30.62, 
Goats: 14.73 
Islam, 2003 
1982 Mymensingh Buffaloes 439 42.36 Islam, 1982 a 
1982  Slaughtered cattle 10,362 42.15 Islam, 1982 b 
1980  Goats 12,344 8.29 Islam, 1980 
 
 
• Humans:   
Data in humans, is usually about case descriptions, and usually about sites where CE occurs rarely. They are 
listed as evidence of the presence of the disease.  
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Year Area Remarks Reference 
2012  Hepatic cyst Islam, 2012 
2012  Spinal hydatid cyst Chowdhury, 2012 
2002-
2011 
Referral hospitals in 
Dhaka 
Hospital base study that concludes that there is active 
transmission of E. granulosus. See Figure 3  
Karim, 2015 
2010  Cranial hydatid abscess Zahed, 2010 





Figure 3: Reported cases of CE (humans) in Bangladesh. Source: Karim 2015 
Echinococcosis | Monograph 12 







• Animals:     
Year Area Species of 
animal 
No. of samples tested % positive Reference 
2014 Slaughterhouses 
in North India 
Cattle, buffaloes, 



























Pednekar et al, 
2009 [23] 
1989 Aligarh Buffaloes, 
camels, sheep, 









Camels: 2 out of 3  
Irshadulla, 1989 






Singh et al, 1988 a 
1988 Bareillly abattoir Buffaloes 3,200 28.6 Singh et al, 1988 b 
 
Summary of published literature on the prevalence of hydatid disease in livestock (expressed as a range) in 
different geographical locations in India; Source: Pednekar et al, 2009 [23].  For the original references, please 
refer to the Pednekar et al paper.  
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• Humans:   
CE is endemic in India; with highest prevalence in Andhra Pradesh and Tamil Nadu. In India, the annual incidence 
of human CE per 105 persons varies from 1 to 200 [24].  
There has been an increase in seropositive cases of echinococcosis from 10.97% in 1984-1998 to 23.12% in 
1999-2003; Casoni's test revealed a similar increase in cases, from 21.38% to 33.83% during the same period in 
northern India. The highest prevalence of human hydatid disease in India has been reported from Andhra 
Pradesh, Saurashtra, and Tamil Nadu [25] 
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There is very limited information.   There is a publication from Margono S, in 2004. It says that before 1988, 
hydatidosis were reported from non-indigenous individuals. In 1988 two indigenous, autochthonous human 
cases were diagnosed as suffering from hydatidosis by clinical and radiological observations, whereas the 3rd 
case in 1997 was confirmed by anamnesis, clinical, radiological and microscopically examinations.  These 3 cases 
were inhabitants of Sulawesi, one of the 5 biggest islands of the archipelago of Indonesia where adult E. 
granulosus was found in dogs.  These findings should alert on the possibility of finding human cases not only in 
Sulawesi, but also in other regions of the country, especially in regions were the parasite was already found in 
several animals.   
 
Myanmar 
No information was found. 
 
Nepal 
• Animals:     
A systematic review was conducted by Devleesschauwer et al [26] in 2014 and it concluded that CE is probably 
endemic in Nepal. It mentioned that CE has traditionally mostly been studied in livestock. The few data in dogs 
indicate higher prevalence in areas where livestock is slaughtered. Since the 2000s, various case reports have 
been published on human hydatidosis. Hospital register studies for CE cases have found low incidences. So far, 
genotyping studies have revealed the presence of G1, the sheep strain in humans, dogs and livestock, G5 (cattle 
strain) in livestock and G6 (camel strain) in humans. 
Year Area Species of 
animal 





Buffaloes 500 10.6 Manandhar et al, 
2006 













Joshi et al, 2000 
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• Humans:      
There are several reports of cases in humans. Below are some examples. 
Rauniyar et al, 2012: Unusual presentation of an isolated extra hepatic hydatid cyst in the paraspinal muscle.  
Joshi A, Shrestha K and Shah LL, 2011: Report on three cases of infected and complicated liver hydatid cysts.   
 
Vietnam 
No information was found. 
 
AFRICA 
There is a very good 2012 review by Wahlers et al [27], of CE in sub-Saharan African.  The specific country 
information for the countries of interest, has been included under each country. Figure 4 below, shows an 
overview of the availability and nature of reported epidemiological data on CE as discussed in the paper.  
http://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(12)70155-X.pdf  
CE is regarded as endemic in sub-Saharan Africa; however, for most countries only scarce data, if any, exist. For 
most of the continent, information about burden of disease is not available; neither are data for the animal 
hosts involved in the lifecycle of the parasite.  Available evidence suggests that several species or strains within 
the E. granulosus complex are prevalent in sub-Saharan Africa and that these strains might be associated with 
varying virulence and host preference. 
CE is highly endemic among the nomadic pastoral tribes of East Africa, but is rare amongst the agriculturally 
based communities [28]. E. granulosus infections are common in dogs from all countries in sub-Saharan Africa 
where they have been examined. Sheep and goats appear to be the most common domestic intermediate hosts, 
but recent studies suggest that camels are equally important intermediate host, especially in Sudan and 
Turkana. At least five of ten E. granulosus genotypes are infective to humans in sub-Saharan African. Most 
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Figure 4: Availability and nature of the reported epidemiological data on CE. Source: Wahlers et al, 2012.  
The prevalences and numbers refer to human cases, unless otherwise specified. 
 
Burkina Faso 
• CE is generally thought to be uncommon in West Africa. In a retrospective survey of CE in Burkina 
Faso, hydatid cysts were found in 10 of about a million animals of various species (original text refers 
to a WHO informal working group as source). No data for human disease are available, but it is 
unlikely to be a major concern in Burkina Faso [27].   
• In a study done in the village of Tougori in 2011, 42 samples tested were negative for E. granulosus 
by ELISA and Western Blot. 
http://www.jidc.org/index.php/journal/article/viewFile/24820474/1074  
Echinococcosis | Monograph 12 







• Livestock:  
The situation in Ethiopia is very well described by Wahlers et al, 2012 [27]:  Several researchers have investigated 
CE in cattle in several parts of Ethiopia, finding regional differences in prevalence and fertility of cysts. The 
highest prevalences were recorded in central Ethiopia with up to 52·7% of 632 cattle being infected with 
Echinococcus spp (26·9% of cysts were fertile). The highest prevalence of fertile cysts was recorded in eastern 
Ethiopia, where 32% of cysts were fertile. The lowest prevalences were recorded in southern parts of central 
Ethiopia, where 16% of 400 cattle were infected (1·8% fertile cysts). Kebede and colleagues argued that in 
northern Ethiopia, sheep might be the main intermediate host for cystic echinococcosis because they recorded 
that 10·6% of 380 sheep were infected, with 56·6% of cysts being fertile. By contrast with these findings, Bekele 
and colleagues did not deem sheep to be the main intermediate host in central Ethiopia, where 16·4% of 560 
tested positive but only 18·3% of cysts were fertile. In goats, low prevalence was recorded in central Ethiopia 
(6·7% of 208),60 whereas Sissay and colleagues noted that 65% of 632 goats examined in eastern Ethiopia were 
infected. Kebede and colleagues also investigated dogs for infection with Echinococcus spp in northern Ethiopia 
where 3 of 18 of eight dogs were infected. In this area, few human cases of cystic echinococcosis were 
identified. In eastern Ethiopia, Mersie and colleagues showed that two of nine dogs were infected with 
Echinococcus spp. In central Ethiopia, mainly E granulosus G1 has been identified in livestock, whereas in 
northern Ethiopia (the city of Makale) E granulosus G1, E ortleppi, and E canadensis G6 and G7 were identified in 
21 cysts from cattle. In a study from central and eastern Ethiopia, E granulosus G1 predominated, but E 
canadensis G6 was also identified, mainly in camels. 
 
Note: there are more publications as can be seen in the following link: 
http://www.ncbi.nlm.nih.gov/pubmed/?term=Hydatid+Ethiopia. Not all have been included, as they are quite 
similar in information.  
Year Area Species of 
animal 





Cattle 473 17.34 Moje 2014 
2013 Adama municipal 
abattoir, Central 
Oromia 
Cattle 422 27.5 Birhanu 2014 
2012-
2013 
Adigrat Cattle 360 18.61 Assefa, 2014 
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Akaki abattoir Camels 770 61.6 Boru et al, 2013 
2010-
2011 
Jijiga abattoir, Somali 
Regional State 





Sheep 1,152 11.6 Desta et al, 2012 
2009-
2010 



























Cattle 632 52.69 Regassa et al, 2010 
2008 Tigray, North 
Ethiopia 
slaughterhouses 































Cattle 107,333 See Table below Getaw 2010 
 
Retrospective data on cattle hydatidosis at Adama abattoir (1997-2007) Source: Getaw 2010 
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o Assefa 2015:  A retrospective analysis covering five years of case reports at two major hospitals in Addis 
Ababa between January 2008 and December 2012 showed that of the total of 25,840 patients admitted 
for ultrasound examination, 27 CE cases were registered, a prevalence of 0.1% and mean annual 
incidence rate of approximately 0.18 cases per 100,000 population. 
o Described by Wahlers et al, 2012 [27]: In Ethiopia, before the introduction of ultrasonography and 
modern serological tests as routine diagnostic instruments, Fuller and Fuller showed that the 
Dassanetch and Nyangatom people from the southwest of the country had a prevalence of CE of up to 
5% on the basis of findings of clinical examination, and more than 5% when the hydatid skin test was 
taken into consideration. The Dassanetch and Nyangatom peoples live in the same geographic area as 
the Turkana people of northwest Kenya, and these populations seem to share customs because they all 
use dogs for cleaning purposes. By contrast, results of an ultrasound survey of the Hamar people of 
southwestern Ethiopia showed a much lower prevalence (0.7% of 990 people) than for the Dassanetch 
and Nyangatom peoples. Macpherson and colleagues did ultrasound surveys of various ethnic groups in 
southern Ethiopia and recorded the highest prevalence in the Nyangatom people (2.9% of 1334). Case 
series have been reported from central Ethiopia. Between 72 and 234 patients were seen over 10–15 
years at hospitals in Addis Ababa. By contrast with other countries, researchers did not identify a female 
predominance in these case series and cases of CE in lung and liver seemed to be much the same, at 
about 40%.  
 
Ivory Coast 
The disease is rare in West Africa. Schmidt published in 1978 the first reports of human cases in Ivory Coast. 
http://www.ncbi.nlm.nih.gov/pubmed/217550.   
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A fourth case was reported in 1982. http://www.ncbi.nlm.nih.gov/pubmed/6293728. However, no more 
recent publications are available. 
Kenya 
The situation in Kenya, has been well summarized by Wahlers et al, 2012 [27]: CE occurs in most parts of the 
country but available data are mostly from Turkana communities in the northwest and from Maasai 
communities in the south. Both communities are nomadic pastoralists rearing huge herds of livestock (sheep 
and goats, cattle, donkeys, and in the Turkana also camels).  
Turkana area: In one serological survey, prevalence of CE was as high as 16.4% in recently settled communities in 
the Turkana area. Results of another serological survey showed regional differences within the Turkana district, 
with a prevalence of 9.4% in north Turkana and 2.1% in south Turkana, which was much the same as in a control 
group from other parts of Kenya.  
Ultrasonography is the most commonly used and most reliable diagnostic technique for surveys. In such surveys, 
the prevalence of CE in the Turkana district was 5.6%. Irvin reported that 4.5% of 791 surgical procedures in one 
hospital were for CE. In clinical cases, a predominance of women has been noted, with women of child-bearing 
age having the highest prevalence. Because most rural hospitals do not have radiograph facilities, lung disease is 
likely to be underdiagnosed.  
A domestic lifecycle of Echinococcus spp with dogs as the definitive host and small ruminants, cattle, and camels 
as intermediate hosts was thought to be most important in the Turkana district. An independent wildlife cycle 
has not been described. Several studies in livestock (ultrasound surveys and abattoir surveys) have been done in 
Turkana. Prevalences of CE varied significantly within Turkana, but generally camels and cattle showed the 
highest prevalences (cattle 19%, camels 61%).  
Maasai area: By contrast with Turkana district, much lower prevalences of CE have been identified in the Maasai 
area of southern Kenya (0.5%, Zeyhle E, unpublished). Despite high infection rates in their livestock and dogs 
and a favourable climate for the survival of echinococcal eggs in the environment, infection in people was much 
lower than in Turkana (0.5% vs 2.5% in 2010, Zeyhle E, unpublished). As in Turkana, sheep and goats seemed to 
be the most important intermediate hosts, but by contrast with the Turkana area an additional wildlife cycle 
probably exists. Although Maasai lead a lifestyle that is much the same as that of the Turkana, they have more 
water available to them for daily living and they do not rely on dogs for cleaning purposes, therefore their dog–
man contact is less close.  
Isolates: Many Echinococcus spp isolates from Kenya have been examined genetically, mainly belonging to E 
granulosus G1 (sheep, goats, cattle, camels, pigs, people, and dogs) and E canadensis G6 and G7 (camels, cattle, 
goats, people, and dogs), and only one to E ortleppi (pig). Most samples originated from the northwest of the 
country (Turkana). In the Turkana district, the sheep strain is the predominant taxon in people, sheep, cattle, 
and goats, whereas the camel strain predominates in camels and partly in goats. Only two isolates of 176 
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hydatid cyst specimens isolated from people were identified as the camel strain (G6) whereas all remaining 
isolates belonged to the sheep strain (G1). 
However, more recent publications, mention an increase of prevalence in the Maasi area (Addy 2012 [29]).  The 
table below shows additional information to the one described by Wahlers  
Year Area Species  No. of samples tested % positive Reference 
2014 Central to 
Northeastern Kenya 














Mbaya et al, 2014 









Addy et al, 2012a 






Addy et al, 2012 b 
2009-
2010 













* Magambo 2011:  Proceedings Hydatidology Congress Urumqui, 2011. Page 48.  
 
• Humans: 
o Although G1 is the E. granulosus genotype most commonly involved in CE in humans, infections with 
G6 (camel strain) might be higher than initially thought.  A study done in 1993-1994 in Turkana 
district, showed that out of 59 isolates, 83% were G1, and 17% were G6.  (Casulli 2010) 
o A more recent publication by Mutwiri et al in 2013 analysed 80 samples from 26 subjects, and found 
85% to be E. granulosus s s (G1-G3), and 15% E. canadensis (G6/7).  
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Four human cases were reported in Madagascar in 1994 ( http://www.ncbi.nlm.nih.gov/pubmed/7575029). No 
more publications were found, despite human cases being reported to the OIE in 2012, 2013 and 2014.  
 
Malawi 
No information has been found.  
 
Mali 
The disease is rare in West Africa, but it has been reported in Niger-Mali-Mauritania, where the camel is the 
main intermediate host (Aubry, 2013).  





Despite being animal and human cases reported to the OIE, the information is very limited.   
In a study of HIV-1 infected people in Beira in 2014, out of 601 patients, 17.3% were seropositive for 
echinococcosis. (http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003121)  
 
Rwanda 
No information available. Disease never reported to OIE.  
 
Senegal 
Cases of human echinococcosis have been reported from Senegal but the reports are from 1970s and 1989. No 
recent publications have been found.   
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In 1965, Verster and colleagues investigated the prevalence of CE in livestock at abattoirs nationwide and results 
are summarised by Wehlers 2012 [27]. Prevalences varied greatly between regions and species investigated. For 
cattle, prevalences ranged between 1.2% and 13.8%, with the highest in the Eastern Cape and the lowest in the 
Karoo. However, the investigators also noted that prevalences increased with age in cattle, and therefore 
differences could be attributable to differences in age of animals slaughtered rather than being true variations in 
prevalence. For sheep, the prevalence ranged from 0·8% in the Karoo to 2·2% in Mpumalanga. For goats, 
prevalence ranged from 0% in the Western Province to 3·2% in the Eastern Cape but the numbers of slaughtered 
animals were small. The dog was regarded as the main definitive host, although infected black-backed jackals 
were identified in the Eastern Cape and Western Transvaal. 
No more recent information has been found.  
• Humans: 
In the last Hydatidology Congress in Romania (October 2015), Mbae et al, mention in the abstract of “CE in sub-
Saharan Africa: new developments” page 20, that in South Africa, hospital data indicate a far larger public health 
impact of CE than previously assumed, but no more details are provided.  
Wahlers in 2011 [30], describes a retrospective data analysis of the National Health Laboratory Service (NHLS) 
laboratory information system on echinococcosis serology, microscopy and histopathology results in eight 
provinces (excluding KwaZula-Natal) on human CE in South Africa. Data from 8 of the 9 South African provinces 
showed that there are a considerable number of cases of CE in South Africa. Even using the most conservative 
estimation by only considering the strongly positive serology and the microscopic demonstration of E. 
granulosus hooklets, about 137 cases per year should be seen in the 8 provinces covered by the database. The 
review of cases of CE presenting to hospitals in Johannesburg demonstrates, however, that in many cases, as to 
be expected – and as underlined by expert critique regarding the meaningfulness of serology in the diagnosis of 
individual CE cases – serology remains negative, so the true number of patients with CE is likely to be 
considerably higher.  
The same data analysed by Mogoye (http://www.ojvr.org/index.php/ojvr/article/viewFile/469/537) showed 
an overall positivity rate in submitted diagnostic samples of 17.0% (1056/6211).  It also became apparent that 
there might be a regional variability in the prevalence of CE, with the highest rates of positive serology and 
microscopic demonstration of requested tests from the Eastern and Western Cape provinces, with the Eastern 
Cape (30.4%), North West (19.0%) and Northern Cape (18.0%) provinces showing highest rates. It has previously 
been reported that about 20 cases of CE are seen at a single hospital in the Eastern Cape annually (Kayser, 
1980). 
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Mogoye also analysed parasite material collected from patients between August 2010 and September 2012 
(http://www.ncbi.nlm.nih.gov/pubmed/23623184) and analyzed by PCR/RFLP methods. A total of 32 samples 





Year Area Species  No. of samples tested % positive Reference 
2013 Ngorongoro District Sheep and 
goats 
180 19.4 Miran, 2013 



















Sheep and goats: 99,401 
Cattle: 4.2 





Tanga city abattoir Cattle Cattle: 12,444 1.56 Swai et al, 2012 
1998-
2001 
Retrospective study 4 
years data from 4 








47.9 Ernest et al, 2009 
1997-
1998 
Mbulu Pigs 70 4.3 Ngowi et al, 2004 
 
• Humans: 
o A retrospective study from 1990 to 2003 in Ngorongoro district (Ernest et al, 2010) reviewed 
hospitalization records.  A total of 171 hydatidosis patients were diagnosed and operated giving an 
average of 13 cases per year, equivalent to approximately 10 cases per 100,000 people per 
year. Women and young people were most commonly affected by cystic echinococcosis. 
Epidemiological data for human disease from other parts of the country are not available.  
Echinococcosis | Monograph 12 






o In 1989, Macpherson et al, undertook an epidemiological study of CE, based on surgical records, in 
the Maasai people.  It showed an annual morbidity of 11 cases per 100,000, with women and 
children being most commonly operated on. With ultrasound examination, the prevalence of CE was 




Year Area Species  No. of samples tested % positive Reference 
2014 Soroti municipal 








Nyero et al, 2015 
2013 Abattoirs in Moroto, 













Six districts of 
Karamoja 











 Omadang 2013: Abstract 21 “Prevalence and economic impact of echinococcosis in livestock among pastoral 
and agor-pastoral communities in selected districts of Uganda” in the Proceedings of the XXV Hydatidology 
Congress in Sudan, November 2013. 
Inangolet 2013*: Abstract 29 “The epidemiology and public Health important of Echinococcosis in pastoralist 
production systems in Karamoja region, Uganda” in the Proceedings of the XXV Hydatidology Congress in Sudan, 
November 2013.  
• Humans: 
o In the last Hydatidology Congress in Romania (October 15), Mbae et al, mention in the abstract of 
“CE in sub-Saharan Africa: new developments” page 20, that the first country-wide ultrasound 
surveys for human CE in Uganda reveal high prevalences in all parts of the country but no details are 
provided.  
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o Othieno et al, reported in the 2013 Hydatidology Congress in Sudan, Abstract 22, (November 2013), 
the results of a cross sectional study done in 2012-2013 in pastoral and agro-pastoral areas in 
Uganda to determine the prevalence of CE in humans by using Ultra sound screening. Surveys were 
done in the Pastoral districts of: Moroto, Napak Nakapiripirit and Amudat in Karamoja region. While 
for agropastoral areas studies were done in the Teso region in the districts of Kumi and Bukedea; in 
Central Uganda, in district of Nakasongola; and in western region in the districts of Kasese and Lwizi. 
Among 2,849 participants sampled 1.61% (n=64) were positive. All districts screened had positive 
cases. Nakasongola had the highest number (4.12%) of CE cases. Nakapiripirit had the least number 
only one case was identified. Generally, more women were affected than men in a ratio of 1:2.07. 
More cases of CE were found in pastoral areas. 
o Hospital records among the Karimojong community and in Western Uganda have shown that on 
average, 20 surgical cases per year of cystic echinococcosis are reported in each of the hospitals in 
Karamoja and Mbarara in Western Uganda (Macpherson 2004, referenced in Inangolet, 2010).  
o There is an old study in humans, from 1975 conducted by Owor and Bitakarame.  They who 
reviewed the accumulated cases between 1967-1972.  Via the national pathology service 23 cases 
were identified retrospectively over a period of 6 years. A female predominance was noted. Most 
cases were imported from Sudan (n=12) and only ten cases occurred in Ugandan people; these 
people were exclusively from the northern and northeastern districts of the country bordering 
southern Sudan and northern Kenya (Turkana). In the district closest to Turkana (Karamoja), where 
five of the ten Ugandan cases originated, 20% of cattle were infected with Echinococcus spp. In the 
two other districts (Acholi and Lango) where human cases were reported, the prevalence in cattle 
was 1%. In another district (Teso) south of the districts from which human cases were reported, a 
prevalence of 10.5% in cattle was noted. About two thirds of dogs in the Moroto district were 




Year Area Species  No. of samples 
tested 
% positive Reference 
2007-
2008 
Two abattoirs in 
Mongu, Western 
Province 








Banda et al, 
2013 
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Data from District 
Vet Officers and 
abattoirs 
Cattle 158,456 See details by 
year in Table 
below. 
Banda et al, 
2013 
 
Annual abattoir prevalence of hydatid cysts based on post-mortem findings in slaughtered cattle Source: Banda 
et al, 2013. 
 
• Humans 
o In the last Hydatidology Congress in Romania (2015), Mbae et al, mention in the abstract of “CE in 
sub-Saharan Africa: new developments” page 20, in Zambia human and livestock CE are moderately 
frequent in the western part of the country. To date, only the cattle-associated E. ortleppi was 
identified in Zambia. 
o In the same Congress, in a different abstract called “Species, genotypes and life cycles: news out of 
Africa” by Romig, page 20, it is mentioned that E. granulosus s.s. is present in all surveyed countries 
(Sudan, Ethiopia, Kenya, Uganda, Zambia, Namibia and South Africa) except Zambia.  E. ortleppi is 
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widespread, but sporadic in most regions, more frequent in some traditional cattle-husbandry areas 
(e.g. western Zambia) and human cases are known, but rare. 
o A retrospective review of, records of human CE from Lewanika General Hospital, which is a referral 
centre for Western Province over a 4 year period (2006 to 2010) was conducted and analysed to 
determine the prevalence of the parasite in humans. Proportion positive in humans was 0.009 % (9 
per 100,000 cases attended to). 67% of the human cases diagnosed were females and 33% male 
humans. http://dspace.unza.zm:8080/xmlui/handle/123456789/3088  
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Economic and Social Impacts at Global 







The WHO mentions in its Third report on neglected tropical diseases “Investing to overcome the global of impact 
of neglected tropical diseases” (2015), that in regions where cystic echinococcosis is endemic the incidence in 
humans can exceed 30/100 000 person-years; prevalences as high as 5–10% may occur in parts of South 
America, Central Asia, China and Africa. The postoperative death rate for surgical patients is 2.2%; 6.5% of cases 
relapse after intervention and require prolonged recovery time. Human echinococcosis can be life-threatening if 
undiagnosed and untreated. Treatment often includes costly surgery. 
Odero et al, in an abstract presented at the XXV Hydatidology Congress in Urumqui (China), 2011, page 170, 
mention that the burden of CE is significant in highly endemic areas. Surgical cyst removal is the main form of 
treatment and, therefore, human CE represents a serious and costly public health challenge in endemic regions. 
Recurrences following surgery usually result in higher morbidity and mortality rates. Use of albendazole and 
percutaneous cyst aspiration provide useful additional treatment of complicated CE at additional cost. Recent 
estimates for the average cost for surgical treatment of CE in UK was >US$ 10,000, and >US$ 4,000 – 6,700 in 
Argentina. In addition to public health impacts, economic losses due to condemnation of affected livestock 
organs are significant.  
In addition to public health impacts, economic losses due to condemnation of affected livestock organs are 
significant.  The WHO mentions in “Investing to overcome the global of impact of neglected tropical diseases” 
(2015), that in livestock, the rate of cystic echinococcosis found in slaughterhouses in hyperendemic areas of 
Latin America varies from 20% to 95% of slaughtered animals. The highest rates have been found in rural areas 
where older animals are slaughtered. In Sardinia, Italy, during 2005–2010 in the absence of specific control 
measures, the prevalence of cystic echinococcosis in sheep was 65%; about 14% of sheep harboured at least one 
fertile cyst. Livestock production losses attributable to cystic echinococcosis include the liver and lungs being 
condemned as unfit for consumption, a reduction in the weight of carcasses, a decrease in the value of the 
animal’s hide, a decrease in milk production and reduced fecundity. 
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Echinococcosis imposes an economic burden in developing countries. Budke et al. [20] estimate the annual global 
economic losses due to CE in livestock to be >US$2B. 
Analysis by the World Bank: 
The World Livestock Disease Atlas – a quantitative analysis of global animal health data [31], published  by the 
World Bank (with cooperation of OIE and FAO) in 2011 is an attempt to understand which livestock diseases 
cause the heaviest losses, which countries suffers the worst disease-related losses and which livestock species 




The World Livestock Disease Atlas bases its analysis on the Livestock Units (LSU).  Each species has a LSU value, 
and the losses of LSU have been given a value.  See Figure 5. For more information on the methodology 
description, please refer to the World Bank Atlas itself (pages 6 & 7). Echinococcosis is one of the top 10 diseases 
causing losses for cattle, buffalos and small ruminants, as shown in Figure 6. However, looking at the data in 






Figure 5: Livestock Units. Source: World Livestock Disease Atlas – The World Bank, 2011 [31]. 
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Figure 6: Top 10 diseases in terms of LSU losses for cattle, buffalo, and sheep & goats. Source: World 
Livestock Disease Atlas – The World Bank, 2011 [31]. 
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Impact on specific focus countries 
 
India 
The first systematic analysis of the livestock and human related economic losses due to cystic 
echinococcosis in India was conducted in 2014 by Singh et al [32].  Data about human cases were 
obtained from a tertiary hospital. Human hydatidosis cases with and without surgical interventions were 
extrapolated to be 5,647 and 17,075 per year assuming a total human population of 1,210,193,422 
in India. Data about prevalence of hydatid cysts in important food producing animals were obtained 
from previously published abattoir based epidemiological surveys that reported a prevalence of 5.39% in 
cattle, 4.36% in buffaloes, 3.09% in pigs, 2.23% in sheep and 0.41% in goats. Animal population data 
were sourced from the latest census conducted by the Department of Animal Husbandry, Dairying and 
Fisheries, India. Other input parameters were obtained from published scientific literature. Probability 
distributions were included for many input values to account for variability and uncertainty. Sensitivity 
analyses were conducted to evaluate the effect of important parameters on the estimated economic 
losses. The analysis revealed a total annual median loss of Rs. 11.47 billion (approx. US $ 212.35 million). 
Cattle and buffalo industry accounted for most of the losses: 93.05% and 88.88% of the animal and total 
losses, respectively. Human hydatidosis related losses were estimated to be Rs. 472.72 million (approx. 
US $ 8.75 million) but are likely to be an under-estimate due to under-reporting of the disease in the 
country. The human losses more than quadrupled to Rs. 1953 million i.e. approx. US $ 36.17 million, 
when the prevalence of human undiagnosed cases was increased to 0.2% in the sensitivity analyses. The 
social loss and psychological distress were not taken into account for calculating human loss. The results 
highlight an urgent need for a science based policy to control and manage the disease in the country. 
 
Nepal 
Impact on humans: Between 2000 and 2012, the annual burden of cystic echinococcosis was calculated 
at 251 DALYs (95% Credibility Interval: 105–458) [26]. 
 
Ethiopia 
Several papers include data about the economic cost of organ condemnation at different abattoirs. Of 
course the annual losses will depend on the number of animals slaughtered and the prevalence of 
hydatid (costs are not presented per animal slaughtered). Some examples are given below:  
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• Brhane and Abebe, 2015: The annual financial losses from organ condemnation due to hepato-
pulmonary bovine hydatidosis at Jimma municipal abattoir were estimated to be 94,485.60 ETB 
or 4,972.93USD 
• Regassa 2010: the total annual economic loss from organ condemnation and carcass weight loss 
due to bovine hydatidosis at Hawassa Municipal abattoir was estimated at 1,791,625.89 
Ethiopian Birr (USD 138,563).  
• Kebede and colleagues estimated the total annual loss from bovine hydatidosis due to offal 
condemnation (lung and liver) and carcass weight loss in the study areas to be 25, 608 Eth. Birr 
(2,807 USD) – Tigray region.  They suggested that the actual loss was even greater because 
home slaughtering practices were common. 
 
Kenya 
As per a report by Odero et al in an abstract presented at the XXV Hydatidology Congress in Urumqui 
(China, 2011, page 170):  
Human infection data for Kenya was obtained from the AMREF database, and livestock data were 
collected from various slaughterhouses in Kenya. In this on-going study, retrospective and prospective 
data on human infection and prevalence in livestock was used to estimate disability-adjusted life years 
(DALYs) for Kenya and calculate the economic losses due hydatid disease infection in livestock. 
Results: From the data analyzed so far, we calculated the average cost to US$ 610 per case for diagnosis 
and treatment (surgery/PAIR) at Kakuma Mission Hospital (Turkana District), where most of cases were 
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Because humans infected with CE pose no risk to other humans, all efforts to control transmission of the disease 
must be implemented either towards reducing the exposure of humans to the parasite (sanitation, exposure to 
infected dogs) or intervention measures directed towards the animal hosts. Considerable efforts have been 
made in many countries to reduce the transmission of E. granulosus with a view to reducing the incidence of 
human CE. The first disease control program for CE was instigated in Iceland in 1863 following the realization 
that a high proportion of the human population suffered from the disease. Some remarkable characteristics of 
the social situation in Iceland at the time facilitated an extremely successful disease control program based 
mainly on public education [33]. CE was recognized as an important concern for human health in other parts of 
the world; for example a national commission of experts was appointed in Argentina in 1906 which elaborated a 
report on measures that should be adopted to prevent transmission of the parasite [34]. However, it was not for 
nearly a century after the initiation of control activities in Iceland and promulgation of evidence of the success of 
the Icelandic campaign that concern for the burden of human CE in other countries led to the establishment of 
concerted control efforts elsewhere. New Zealand was the first country to instigate serious CE control activities 
in the 20th century. Shortly after a formal hydatid control campaign began in New Zealand in 1959, a voluntary 
education campaign to control CE disease was established in Tasmania, Australia, which subsequently expanded 
into a formal government-funded program in 1965  [33]. Since that time the United Nation agencies, the Food and 
Agriculture Organization (FAO), Pan American Health Organization (PAHO), World Health Organization (WHO), 
United Nations Environment Program (UNEP) and the Office International des Epizooties (OIE) undertook a 
series of workshops and other activities concerning echinococcosis [35]. Subsequently, new CE control activities 
were initiated in many countries of the world [36] and the current WHO/OIE guidelines were prepared concerning 
the surveillance, prevention and control of echinococcosis [3]. The disease control activities in different countries 
have varied enormously in their effectiveness, with some leading to the complete elimination of the disease 
while others have failed almost completely to have any impact.  
Dr Michael Gemmell prescribed various options and decision making processes that provide a rational basis for 
undertaking control activities (Gemmell 1987; Gemmell 1995 [42]; Gemmell et al. 1986a, 1987; Gemmell and 
Roberts 1998 (43); Gemmell et al. 2001 – all referenced in Lightowlers 2012 [41]). This theoretical basis became 
an integral part of the 2001 update to the WHO/OIE Guidelines on echinococcosis and remains recognized to 
this time [13].  
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During the latter half of the 20th century many separate activities were commenced with the aim being to 
reduce the prevalence of CE in humans. Those that were successful have tended to be reviewed 
comprehensively in publications while those that were less successful have often not been the subject of 
detailed publications that could provide information about why those control activities were not successful 
[36][38]. A comprehensive reference to CE control activities around the world can be found in the report of a 
PAHO/WHO Working Group meeting held in San Carlos de Bariloche, Argentina, during September 1999 [36]. In 
spite of efforts to control transmission of E. granulosus in many parts of the world, the disease remains 
prevalent in humans throughout many regions of the world. There remains an urgent need for new 
echinococcosis control activities and the implementation of improved methods for controlling transmission of 
the disease. 
The various control campaigns that have been undertaken to date have employed a wide variety and 
combination of measures and, because each country has presented unique political and social circumstances, it 
is difficult to prescribe universal measures for all situations. Constraints on which particular control measures 
are applicable in different regions and countries can have great impacts on the effectiveness of the control 
efforts. For example, stray dogs pose a serious problem for CE transmission. They predate hosts such as sheep 
and goats and they are near impossible to include in an anthelmintic dosing regimen. The political and social 
situation in Sardinia prevented stray dogs from being euthanized as part of CE control measures implemented in 
the 1990’s; rather they were required to be maintained, for life, in pounds. In stark comparison, the problem 
with stray dogs was solved in Cyprus with the euthanasia, mostly by shooting, of 82,984 dogs [39]. In the year 
1971 alone, 27,552 dogs were destroyed, equating to 75 dogs every day. Social and farming practices also have 
major influences. For example, in Sardinia the sheep are used almost exclusively for milking. The old animals 
have little meat value and very few are sent to abattoirs for slaughter. Rather, they are either slaughtered on-
farm with the hydatid infected offal discarded, or they simply die in the fields [40].  Although it is difficult to draw 
general conclusions from examining the effectiveness of CE control measures in different countries, 
consideration of the successes and failures does provide some clues as to which control activities may be of 
value for future CE control initiatives. Lightowlers [41] examined selected examples of campaigns that led to 
complete eradication of the disease as well as an example where initial efforts failed but where more recent 
changes to the control measures have led to success. Also, Gemmell and his colleagues have compared and 
contrasted the CE control programs undertaken around the world, highlighting features that have favored either 
success or failure. Voluntary public education measures appear to have been almost universally ineffective in 
bringing about a substantial decrease in disease transmission. The exception is Iceland where some 
extraordinary circumstances there led to education being effective. After praziquantel became available as a 
highly effective taeniacide for dogs, it became incorporated as an integral component of all active CE control 
programs. However, its frequency of use and whether it is delivered by control program staff or the dog owners 
themselves have significant impacts on the effectiveness of the drug for controlling disease transmission. 
Gemmell [42] and Gemmell and Roberts [43] highlight the surety of on-going funding for control programs as being 
a vitally important factor in the likelihood that CE control will be effective. Where funding has been adequate, 
dog treatments have been undertaken by trained staff of the control program (eg New Zealand and Tasmania, 
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Wales 1983-9). Where insufficient funds have been available, taeniacides have been distributed to dog owners 
or dog owners have been expected to purchase the treatments themselves, leading to problems with 
compliance. 
A vaccine has been developed which can greatly reduce transmission of E. granulosus by livestock animals. This 




In humans, treatment with benzimidazole drugs, principally albendazole, forms an important aspect of disease 
management.  However, to be effective the drugs are required to be given in large amounts over long periods of 
time. No practical treatment has been developed for livestock animals.  Dogs infected with Echinococcus spp. 
can be treated with a single dose of praziquantel. The treatment is virtually 100% effective and, to date, it has 
formed the mainstay of CE control program worldwide. However, there is no effective immunity in dogs to re-
infection with Echinococcus. In the absence of effective control measures being implemented in the 
intermediate hosts, unless the drug is applied as intervals of 6 weeks or less, treated dogs can be readily re-




A single effective vaccine has been developed for livestock animals – see Section 6 for more details.   
 
Options and strategies for control programs at national, sub-national or regional level 
Control measures for echinococcosis are aimed at breaking the cycle of transmission and involve four main 
components: 
1. Control of non-owned dogs.  In many parts of the world, feral or semi-feral dogs contribute significantly to 
CE transmission.  However, in most parts of the world it is difficult or impossible to implement control 
measures in these animals.  There is no effective vaccine for E. granulosus in dogs and little prospect that an 
effective vaccine could be developed (see Section 6). Euthanasia of dogs is resisted strongly by the 
communities in many areas where CE is endemic. Treatment of the animals with praziquantel is impractical 
due to the frequency with which dog treatments need to be implemented for this control measure to be 
effective.  
Echinococcosis | Monograph 12 






2. Prevention of dogs gaining access to infected offal. Several common practices that occur in areas where CE is 
highly prevalent contribute to disease transmission.  The practice of home slaughter of sheep or goats often 
leads to unsightly, infected offal being deliberately given to dogs. Otherwise, lax disposal practices with 
home slaughtered animals also provides access for dogs to infected offal.  Formal abattoirs often exhibit 
poor control practices over condemned materials such that dogs gain access to these.  Preventing each of 
these practices can reduce transmission of CE, however changing people’s behavior concerning home 
slaughter has been found to be very difficult except in relatively wealthy, highly literate societies. 
3. Treatment of dogs.  Frequent treatment of dogs with praziquantel has been the cornerstone of most efforts 
to control CE. However, the high frequency with which the drug must be administered has been a major 
limitation to most CE control programs that have relied on dog treatment.  Furthermore, dog dosing by the 
animal owners has been found to be very unreliable, and the cost of employing staff to directly implement a 
dog dosing practice has proven prohibitive in most CE control programs.  
4. Quarantine of infected livestock.  This practice has been used in the final phases of a small number of 
control programs that have been effective and where the programs have brought the disease towards 
elimination.  It is not practical for livestock quarantine to play a more extensive role in CE control, 
particularly because of the inadequacy of available diagnostic methods for CE in livestock. 
5. Vaccination.  Data are becoming available from the first field applications of the EG95 livestock vaccine in a 
CE control program [44]. Details are provided in Section 6. 
Mathematical modelling of the transmission parameters for CE using various CE control options including the 
EG95 vaccine, showed that the use of vaccination together with relatively infrequent treatment of dogs, 
provided the optimal level of control with a relatively minimal cost in terms of the interventions involved.  
Vaccination plus dog treatments would be effective in situations where it is very difficult or impossible to 
achieve some other measures, such as control of stray dogs [45]. 
Control of echinococcosis in wildlife 
Control measures applied to wildlife animals forms the basis on which efforts have been made to reduce 
transmission of AE in Europe (use of praziquantel-containing baits for European foxes).  Although wildlife is 
known to contribute to some degree to CE transmission in many parts of the world, nowhere in the world where 
the disease is highly endemic is wildlife transmission considered to be a major source of human infection and CE 
control measures are more appropriately directed towards domestic transmission of the disease rather than 
sylvatic transmission.  An implication of the transmission of CE via wildlife is that elimination of CE is not feasible 
in many parts of the world due to sylvatic transmission.  For example, E. granulosus has been introduced to the 
Australian continent through the importation of sheep some 200 years ago and the parasite has become 
endemic down the eastern seaboard, transmitted by wild dogs (dingos) and macropod marsupials.  The disease 
constantly spills over to infect livestock and humans living adjacent to forest areas where the sylvatic 
transmission occurs [46]. 
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Table 5: Official status, official programs and treatment for echinococcosis/hydatidosis in the countries of 
interest. Information provided by the questionnaire sent to the DG/DVS as part of this monograph. Replies 























Bangladesh Yes No No - - 
Myanmar (Burma) No No No No Yes 
Nepal No Yes, passive No Yes Yes 
Vietnam No No No - - 
AFRICA 
Côte d'Ivoire (Ivory 
Coast) 
Yes Yes, passive but 
active if outbreaks 
No - - 
Kenya Yes Yes, passive at 
abattoir 
No Yes Yes 
Malawi No No No N/A N/A 
Mali N/A N/A N/A N/A N/A 
Rwanda  - - - - - 
Tanzania  Yes Yes, active No No No 
Uganda No No No N/A N/A 
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Table 6: Official status, official programs and treatment for echinococcosis/hydatidosis in the countries of 
interest. Information provided by the questionnaire sent to the DG/DVS as part of this monograph. Replies 

















Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
ASIA 
Bangladesh No - - - 
Myanmar (Burma) No - - - 
Nepal No - - - 
-Vietnam No - - - 
AFRICA 
Côte d'Ivoire (Ivory 
Coast) 
No - - - 
Kenya N/A N/A N/A N/A 
Malawi No N/A N/A N/A 
Mali N/A N/A N/A N/A 
Rwanda  - - - - 
Tanzania  No Not done Not done Not done 
Uganda No Never vaccinated N/A N/A 
Zambia No N/A N/A N/A 
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Commercial vaccines manufactured in Africa and Asia  
 
There are no vaccines listed under The Center for Food Security and Public health, Iowa State University 
(www.cfsph.iastate.edu/vaccines/index.php and Vetvac (www.vetvac.org) databases.    
 
Commercial vaccines imported into Africa and Asia (countries of interest) 
 
There are no commercial vaccines for hydatid licensed to use in the countries of interest, and there is no 




No combination vaccines are in use or available for echinococcosis.  However, combination of EG95 together 
with other livestock vaccines, particularly clostridial vaccines, would be an obvious advantage and could solve 
the difficulties experiences with adoption of EG95 vaccination due to the lack of incentive for livestock owners 
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The Target Product Profiles (TPPs) reflect the availability and utility of current agents and incorporate features 
that will be necessary to improve on the current products and to address unmet needs, taking into account the 
particular requirements of the poorest livestock keepers.   
The TPPs are more robust when they include the opinions and consider the needs of the different stakeholders.  
While efforts have been made to encompass them, the TPP showed in Table 7 below, should be considered a 
proposal, a live document subject to improvements.  
Minimum characteristics are based on information available concerning the EG95 vaccine produced at UM, and 
Hidatil EG95 produced by Tecnovax (Argentina). 
http://www.sani.com.ar/producto_imprimir.php?id_producto=5643 .  Note that UM is a freeze dried vaccine, 
while the one from Argentina has an oil adjuvant.  
Table 7: Official status, official programs and treatment for echinococcosis/hydatidosis in the countries of 
interest. Information provided by the questionnaire sent to the DG/DVS as part of this monograph. Replies 
were not received from India, Indonesia, Burkina Faso, Ethiopia, Madagascar, Mozambique, Senegal and 
South Africa. 
 





Immunogen with protective 
antigens for E. granulosus s s 
(Genotypes 1-3)  
Immunogen with protective antigens for E. 
granulosus ALL genotypes. 
2 Indication for use For active immunization of sheep 
and goats.  
For active immunization of sheep, goats, 
cattle, camels and pigs.  
3 Recommended species 
 
Sheep and goats. All susceptible livestock, including 
susceptible wildlife. 
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4 Recommended dose 
 
1 ml (50µg recombinant protein) Same dose for all species (1 or 2 ml) 
5 Pharmaceutical form 
 
Freeze dried or liquid Ready to use solution/suspension 
6 Route of administration 
 
SC or IM SC, Intramuscular or oral (bait vaccine, this 
last route, very important for wildlife) 
7 Regimen - primary 
vaccination 
Two doses, 30 days apart.  Single lifetime dose 
8 Regimen - booster Revaccinate annually.  Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance Protection against E. granulosus   Protection against B. anthracis and all 
possible mutants 
10 Recommended age at first 
vaccination 
From 3 months of age From 1-2 months of age, when other 
vaccines are applied.  
11 Onset of immunity 
 
 
<7 days (very important for outbreaks) 





13 Expected efficacy To prevent disease & prevent 
transmission. 
To prevent infection and transmission in 
100% of the animals.  
14 Expected safety It can generate a mild local 
reaction. 
No post-vaccinal reactions at any age. Safe 
for pregnant animals at any stage.  
Safe for all sexes at any age.  
15 Withdrawal period 
 
Nil Nil for milk and meat 
16 Special requirements for 
animals 
Do not vaccinate un-healthy 
animals. 
 
Vaccinate all animals 
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17 Special requirements for 
persons 
 None None 
18 Package size 
 
100 – 125 doses Multiple pack size from 5 doses 
19 Price to end user 
 
Tecnovax is selling vaccine to a 
region in Chile at USD 1,80 – 1,90 
per dose 
(extremely high).  
< USD 0.10 
20 Storage condition and shelf-
life as packaged for sale 
Stable at 4-8°C for 24 months 
 
Stable at 30°C for 24 months 
 
21 In-use stability 
 
  24 hours or greater 
22 Other: potential combinations  Combined with clostridial vaccines or any 
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Scientific quality: The publications and data from the different research groups, should be carefully evaluated.  
The use of good science and good experimental design with use of proper controls, adequate numbers, suitable 
challenge model, reproduction of results by them and by independent groups, and appropriate analysis has not 
been verified for this monograph.  If any of these projects were to be pursued, a detailed peer review taking into 
account the above considerations is strongly recommended.   
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ANNEX 1:  Additional data on disease presence 
and incidence 
Reports to OIE on echinococcosis/hydatidosis: 
Note: The OIE changed the definitions of the diseases in 2014.  Therefore, there are 2 graphs for each region.  
One covering from 2005-2013 (that does not differentiate the different types of Echinococcus), and another one 
for 2014-2015, specific for E. granulosus. 
 
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals.  
Echinococcosis/hydatidosis in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam (2005-2013) 
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Infections with E. granulosus in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam (2014-2015) 
 
Echinococcosis/hydatidosis in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal (2005-2013) 
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Infections with E. granulosus in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal (2014-2015) 
 
Echinococcosis/hydatidosis in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda (2005-2013) 
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Infections with E. granulosus in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda (2014-2015) 
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Infections with E. granulosus in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
(2014-2015) 
 
 
 
 
 
 
